骨髓瘤药物耐药性的新兴研究主题:一个25年的图书统计和可视化分析
Xin He1, Wanquan Cao1, Jialun Wang1
1Department of Orthopedics, Chengdu Fifth People's Hospital, Chengdu, China.
Naunyn-Schmiedeberg's archives of pharmacology
|October 7, 2025
概括
在骨髓瘤中,耐药性阻碍了治疗. 研究表明,传统机制正在向自和免疫疗法等新兴领域转变,这表明需要新的个性化策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 图书统计学 图书统计学
背景情况:
- 骨髓瘤药物耐药性是影响患者生存的重大挑战.
- 目前的治疗方法由于内在和获得的耐药性机制而面临局限性.
研究的目的:
- 对骨髓瘤药物耐药性的全球研究趋势进行文献计量和可视化分析.
- 确定从2000年到2025年在该领域不断发展的研究主题和新兴领域.
主要方法:
- 从 Web of Science 核心收藏中对 927 篇英语文章和评论进行了图书统计分析.
- 使用VOSviewer,CiteSpace,Scimago Graphica和Charticulator进行可视化.
- 分析出版趋势,领先的国家,主题演变和关键词爆发.
主要成果:
- 年度出版物的持续增长,中国和美国是主要贡献者.
- 从P-糖蛋白和亡转向自,EMT,非编码RNA,瘤微环境和纳米医学.
- 越来越多的人对免疫疗法,铁,代谢脆弱性和外体细胞介导耐药性感兴趣.
结论:
- 骨髓瘤耐药性的领域是动态的,新兴的重点是新的途径.
- 跨学科的方法,包括空间奥米克,免疫代谢和精确的药物输送至关重要.
- 未来的研究应该整合这些见解来开发个性化的治疗策略,以改善患者的治疗结果.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K


